Literature DB >> 17905100

Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors.

Kadir Türkölmez1, Hüsnü Tokgöz, Berkan Reşorlu, Kenan Köse, Yaşar Bedük.   

Abstract

OBJECTIVES: To establish whether a difference in the clinical outcomes of patients with progressive and primary muscle-invasive bladder cancer exists.
METHODS: The records of patients who had undergone radical cystectomy for bladder urothelial carcinoma from 1990 to 2005 were reviewed. According to our inclusion criteria, 109 patients with primary muscle-invasive tumor (group 1) and 45 patients with progressive tumors were selected (group 2). The correlation of clinical and pathologic variables with survival was investigated using the Cox proportional hazards test. The Kaplan-Meier method was used to estimate progression rates. Multivariate analysis was performed using the Cox regression survival method to investigate possible predictive factors.
RESULTS: The 2, 3, and 5-year cancer-specific survival rate was 72%, 61%, and 43% for patients with progressive tumor and 75%, 62%, and 54% for patients with primary tumor, respectively (P >0.05). For lymph node-negative tumors (pN0), the corresponding rates were 77%, 64%, and 56% in group 1 and 73%, 60%, and 39% in group 2 (P >0.05). On multivariate analysis, lymphovascular invasion and pT stage of the primary tumor remained significant independent prognostic factors for cancer-specific survival. The detection of local and/or distant metastasis during follow-up significantly shortened the cancer-specific survival of patients with muscle-invasive bladder cancer.
CONCLUSIONS: The results of our study have shown that patients with progressive muscle-invasive urothelial tumors do not have a worse prognosis than do those with primary tumors. During the early postoperative years, even patients with progressive tumors had better disease-specific survival rates. For both groups, pT stage and lymphovascular invasion seemed to be independent predictors of decreased cancer-specific survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905100     DOI: 10.1016/j.urology.2007.05.008

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  22 in total

1.  Lymphovascular invasion as a predictive factor for muscle-invasive bladder cancer and its importance in a bladder-conservation treatment group.

Authors:  Hüsnü Tokgöz; Bulent Erol
Journal:  Curr Oncol       Date:  2010-04       Impact factor: 3.677

Review 2.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.

Authors:  Romain Mathieu; Ilaria Lucca; Morgan Rouprêt; Alberto Briganti; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2016-07-19       Impact factor: 14.432

3.  Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients.

Authors:  Rania Bakry; Mohamed I El-Sayed; Hesham M Hamza; Khaled H Hassan
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

4.  CCR7 as a predictive biomarker associated with computed tomography for the diagnosis of lymph node metastasis in bladder carcinoma.

Authors:  Jinbo Chen; Y U Cui; Longfei Liu; Chao Li; Yunhua Tang; X U Zhou; Lin Qi; Xiongbing Zu
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

5.  Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?

Authors:  Ahmed F Kotb; Evan Kovac; Wassim Kassouf; Joe Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Darrel Drachenberg; Armen G Aprikian
Journal:  World J Urol       Date:  2012-12       Impact factor: 4.226

Review 6.  Pharmacogenomics in bladder cancer.

Authors:  Garrett M Dancik; Dan Theodorescu
Journal:  Urol Oncol       Date:  2014-01       Impact factor: 3.498

7.  Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.

Authors:  Guido Dalbagni; Kinjal Vora; Matthew Kaag; Angel Cronin; Bernard Bochner; S Machele Donat; Harry W Herr
Journal:  Eur Urol       Date:  2009-07-17       Impact factor: 20.096

8.  Completeness of bladder cancer staging in the Danish Cancer Registry, 2004-2009.

Authors:  Louise Holland-Bill; Trine Frøslev; Søren Friis; Morten Olsen; Niels Harving; Michael Borre; Mette Søgaard
Journal:  Clin Epidemiol       Date:  2012-08-17       Impact factor: 4.790

Review 9.  Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.

Authors:  Mario Pones; David D'Andrea; Keiichiro Mori; Mohammad Abufraj; Marco Moschini; Eva Comperat; Shahrokh F Shariat
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

10.  Predictive Nomogram and Risk Factors for Lymph Node Metastasis in Bladder Cancer.

Authors:  Zijian Tian; Lingfeng Meng; Xin Wang; Tongxiang Diao; Maolin Hu; Miao Wang; Yaqun Zhang; Ming Liu
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.